Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Harvard Business School
Dow
AstraZeneca
Baxter

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Estrogens, conjugated synthetic b - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for estrogens, conjugated synthetic b and what is the scope of freedom to operate?

Estrogens, conjugated synthetic b is the generic ingredient in one branded drug marketed by Aspen and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Estrogens, conjugated synthetic b has seventeen patent family members in nine countries.

There are three drug master file entries for estrogens, conjugated synthetic b.

Summary for estrogens, conjugated synthetic b
International Patents:17
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 3
Clinical Trials: 6
Formulation / Manufacturing:see details
DailyMed Link:estrogens, conjugated synthetic b at DailyMed
Recent Clinical Trials for estrogens, conjugated synthetic b

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duramed ResearchPhase 4
Stanley Medical Research InstitutePhase 2
The AlfredPhase 2

See all estrogens, conjugated synthetic b clinical trials

US Patents and Regulatory Information for estrogens, conjugated synthetic b

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-005 Apr 27, 2007 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-005 Apr 27, 2007 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
McKesson
Baxter
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.